

Denka Completes Investment in Startup Developing Wearable Electronic Stethoscope ~ A New Era of Digital Health Realized through AI and Chemistry ~

Tokyo, Japan - Denka Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President: Toshio Imai) is pleased to announce the successful completion of its investment in Aevice Health Pte Ltd. (Headquarters: Singapore; CEO: Adrian Ang; hereinafter referred to as “Aevice Health”) as part of the company’s Pre-Series A funding round. The investment was made through Denka’s corporate venture capital (CVC) fund, jointly operated with Pegasus Tech Ventures.

Aevice Health is a pioneering digital health company focused on improving the management of chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD) (*). By leveraging its proprietary technology, Aevice Health has developed the “AeviceMD,” a smart wearable AI-powered electronic stethoscope integrated with a remote monitoring platform. This innovative solution enables continuous tracking of key respiratory and cardiac health metrics, including abnormal respiratory sounds, respiratory rate, and heart rate, providing valuable insights into the progression of a patient’s condition. The company currently operates in Singapore and the United States.

Through this investment, Denka aims to deepen our initiatives in the healthcare field, with a particular focus on “prevention, diagnosis, and treatment”. By integrating Aevice Health’s AI-powered electronic stethoscope technology with Denka’s expertise in respiratory infectious diseases and immunology, Denka strives to further advance our efforts in digital health and address medical challenges. Additionally, Denka will engage in joint research and development of new AI technologies in the field of respiratory diseases and related disease areas.

Denka established its CVC fund in January 2023 as part of its long-term management plan, “Mission 2030”, which aims to drive the creation of new businesses through strategic investments in startups with cutting-edge technologies worldwide. With a commitment of up to USD 100 million in CVC initiatives by fiscal year 2030, Denka seeks to leverage its world-class expertise in chemistry to improve lives and contribute to society globally, aligning with its vision of “becoming specialists who make the world better through the power of chemistry”.

(*) Chronic Obstructive Pulmonary Disease (COPD)

A general term for diseases previously known as chronic bronchitis and emphysema

It is a lifestyle disease caused by long-term smoking, and it is estimated that there are over 5 million patients in Japan

<Aevice Health Pte Ltd.>

- Head Office : 18 Howard Road, #06-11, Novelty BizCentre, Singapore 369585
- Business Overview : Disease management services with wearable stethoscopes and remote monitoring platforms
- Official website : <https://www.aevice.com/>



[Reference: Past press releases related to this matter (our official website)]

- January 17, 2023: Signing ceremony for the establishment of CVC (Corporate Venture Capital)

https://www.denka.co.jp/eng/storage/news/pdf/476/20230117_denka_cvc_en.pdf

【Inquiries from the press】

Corporate Communications Department Tel: 03-5290-5511

【Inquiries from customers】

New Business Development Department, New Business Creation Department

Tel: 03-5290-5522